DNA-demethylation by DAC induces expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets.

Cancer testis antigens (CTAs) can be expressed in tumors, whereas expression is silenced in normal tissue except for the immune-privileged testis. This quasi-tumor-restricted expression makes CTAs attractive targets for T cell receptor (TCR) gene therapy. However, CTA-specific TCR gene therapy is only applicable for tumors with substantial and homogeneous CTA expression.

T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines.

Not available.

Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody.

Antibody-epitope conjugates (AECs) proved to be a promising new therapeutic strategy to redirect virus-specific CD8 T cells toward cancer cells by delivering T-cell epitopes. To be able to redirect a larger fraction of the virus-specific T-cell population, it is beneficial to deliver a broader selection of T-cell epitopes. We investigated two different methods to generate AECs with two distinct virus-specific T-cell epitopes fused to one antibody.

Imaging mass cytometry reveals the order of events in the pathogenesis of immune-mediated aplastic anemia.

The autoimmune response driving hematopoietic stem and progenitor cell (HSPC) destruction in immune-mediated aplastic anemia (AA) remains incompletely understood. We previously identified a disease-specific immune cell network involving T, B, and myeloid cells. However, the interactions within this network, the interaction with the microenvironment, and the chronological events in AA development, remain unclear.